International guidelines

Rest of the world

NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian, pancreatic, and prostate[18]

Published by:National Comprehensive Cancer Network

Last published:2025

NCCN clinical practice guidelines in oncology: breast cancer[25]

Published by:National Comprehensive Cancer Network

Last published:2024

ACR appropriateness criteria: female breast cancer screening​ [63]

Published by:American College of Radiology

Last published:2023

Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[52]

Published by:American Society of Clinical Oncology; College of American Pathologists

Last published:2023

Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update[56]

Published by:American Society of Clinical Oncology

Last published:2023

Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR[64]

Published by:American College of Radiology

Last published:2023

​Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer: ASCO guideline rapid recommendation update[104]

Published by:American Society of Clinical Oncology

Last published:2023

ACR practice parameter for the performance of contrast-enhanced magnetic resonance imaging (MRI) of the breast​​[62]

Published by:American College of Radiology

Last published:2023

Nutrition and physical activity guideline for cancer survivors[182]

Published by:American Cancer Society

Last published:2022

Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update[149]

Published by:American Society of Clinical Oncology

Last published:2022

Treatment for brain metastases[181]

Published by:American Society of Clinical Oncology; Society for NeuroOncology; American Society for Radiation Oncology

Last published:2022

ACR appropriateness criteria: imaging after breast surgery[65]

Published by:American College of Radiology

Last published:2022

Chemotherapy and targeted therapy for human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline rapid recommendation update[103]

Published by:American Society of Clinical Oncology

Last published:2022

Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update​​[139]

Published by:American Society of Clinical Oncology

Last published:2022

ACR appropriateness criteria: palpable breast masses​​[66]

Published by:American College of Radiology

Last published:2022

Exercise, diet, and weight management during cancer treatment: ASCO guideline[183]

Published by:American Society of Clinical Oncology

Last published:2022

Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update​​[55]

Published by:American Society of Clinical Oncology

Last published:2022

ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer[24]

Published by:European Society for Medical Oncology

Last published:2021

ACR appropriateness criteria: plexopathy[184]

Published by:American College of Radiology

Last published:2021

Chemotherapy and targeted therapy for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor-negative: ASCO guideline update[102]

Published by:American Society of Clinical Oncology

Last published:2021

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer[161]

Published by:Society for Immunotherapy of Cancer

Last published:2021

Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update[80]

Published by:American Society of Clinical Oncology

Last published:2021

Estrogen and progesterone receptor testing in breast cancer[67]

Published by:American Society of Clinical Oncology; College of American Pathologists

Last published:2020

Bone health in cancer[174]

Published by:European Society for Medical Oncology

Last published:2020

Breast cancer screening for average-risk women: recommendations from the ACR Commission on Breast Imaging[68]

Published by:American College of Radiology

Last published:2017

Role of bone-modifying agents in metastatic breast cancer[172]

Published by:American Society of Clinical Oncology; Cancer Care Ontario

Last published:2017

Advanced breast cancer: diagnosis and treatment[70]

Published by:National Institute for Health and Care Excellence (UK)

Last published:2017

Endocrine therapy for hormone receptor-positive metastatic breast cancer[79]

Published by:American Society of Clinical Oncology

Last published:2016

Screening for breast cancer[69]

Published by:US Preventive Services Task Force

Last published:2016

Breast cancer follow-up and management after primary treatment[185]

Published by:American Society of Clinical Oncology

Last published:2013

Use of this content is subject to our disclaimer